Incidence of and risk factors for postoperative urinary retention in fast-track hip and knee arthroplasty

Lars S Bjerregaard, Stina Bogø, Sofie Raaschou, Charlotte Troldborg, Ulla Hornum, Alicia M Poulsen, Per Bagi, Henrik Kehlet, Lars S Bjerregaard, Stina Bogø, Sofie Raaschou, Charlotte Troldborg, Ulla Hornum, Alicia M Poulsen, Per Bagi, Henrik Kehlet

Abstract

Background and purpose: Postoperative urinary retention (POUR) is a clinical challenge, but there is no scientific evidence for treatment principles. We describe the incidence of and predictive factors for POUR in fast-track total hip (THA) and knee arthroplasty (TKA).

Patients and methods: This was a prospective observational study involving 1,062 elective fast-track THAs or TKAs, which were performed in 4 orthopedics departments between April and November 2013. Primary outcome was the incidence of POUR, defined by postoperative catheterization. Age, sex, anesthetic technique, type of arthroplasty, and preoperative international prostate symptom score (IPSS) were compared between catheterized and non-catheterized patients.

Results: The incidence of POUR was 40% (range between departments: 30-55%). Median bladder volume evacuated by catheterization was 0.6 (0.1-1.9) L. Spinal anesthesia increased the risk of POUR (OR = 1.5, 95% CI: 1.02-2.3; p = 0.04) whereas age, sex, and type of arthroplasty did not. Median IPSS was 6 in non-catheterized males and 8 in catheterized males (p = 0.02), but it was 6 in the females in both groups (p = 0.4).

Interpretation: The incidence of POUR in fast-track THA and TKA was 40%, with spinal anesthesia and increased IPSS in males as predictive factors. The large variation in perioperative bladder management and in bladder volumes evacuated by catheterization calls for randomized studies to define evidence-based principles for treatment of POUR in the future.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4404768/bin/ORT-86-183-g001.jpg
Urine volumes evacuated at the first intermittent catheterization postoperatively (n = 414).

References

    1. Balderi T, Carli F. . Minerva Anestesiol. 2010;76(2):120–30.
    1. Balderi T, Mistraletti G, D’Angelo E, Carli F. . Minerva Anestesiol. 2011;77(11):1050–7.
    1. Baldini G, Bagry H, Aprikian A, Carli F. . Anesthesiology. 2009;110(5):1139–57.
    1. Barry MJ, Fowler FJ, Jr., O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. . J Urol. 1992;148(5):1549–57.
    1. Bjerregaard LS, Bagi P, Kehlet H. . Acta Orthop. 2014;85(1):8–10.
    1. Choi S, Awad I. . Curr Opin Anaesthesiol. 2013;26(3):361–7.
    1. Elkhodair S, Parmar HV, Vanwaeyenbergh J. . Surgeon. 2005;3(2):63–5.
    1. Griesdale DE, Neufeld J, Dhillon D, Joo J, Sandhu S, Swinton F, Choi PT. . Can J Anaesth. 2011;58(12):1097–104.
    1. Groutz A, Blaivas JG, Fait G, Sassone AM, Chaikin DC, Gordon D. . J Urol. 2000;163(1):207–11.
    1. Harsten A, Kehlet H, Toksvig-Larsen S. . Br J Anaesth. 2013;111(3):391–9.
    1. Husted H, Solgaard S, Hansen TB, Soballe K, Kehlet H. . Dan Med Bull. 2010;57(7):A4166.
    1. Kaplan SA. Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl 4):S10–S17.
    1. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. . J Urol. 2008;180(1):47–54.
    1. Kehlet H. . Lancet. 2013;381(9878):1600–2.
    1. Kieffer WK, Kane TP. . Ann R Coll Surg Engl. 2012;94(5):356–8.
    1. Kotwal R, Hodgson P, Carpenter C. . Acta Orthop Belg. 2008;74(3):332–6.
    1. Madersbacher H, Cardozo L, Chapple C, Abrams P, Toozs-Hobson P, Young JS, Wyndaele JJ, De WS, Campeau L, Gajewski JB. . Neurourol Urodyn. 2012;31(3):317–21.
    1. Pavlin DJ, Pavlin EG, Gunn HC, Taraday JK, Koerschgen ME. . Anesth Analg. 1999;89(1):90–7.
    1. Sarasin SM, Walton MJ, Singh HP, Clark DI. . Ann R Coll Surg Engl. 2006;88(4):394–8.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever